SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
King Charles shares cancer treatment update, says it's a 'personal blessing' - 2How a seabird native to Hawaii has adapted to life in Honolulu's concrete jungle
- 3April’s full pink moon will rise in the night sky this week
- 4Ferrari Cavalcade Suspended After High-Speed Crash in Argentina Involving a Purosangue
- 5Satellite space quiz: What's orbiting Earth?
- An Extended time of Self-Reflection: Self-awareness through Journaling
- Bad flu season getting worse; skyrocketing cases set state record
- Rachael Ray is navigating grief this holiday season. She doesn't have time for 'negative energy' on the internet.
- 'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed
- French high-speed train slams into truck, killing TGV driver
- Cuba fights to contain spread of mosquito-borne chikungunya virus
- Inside the alleged Russian operation to trigger anti-government protests in Angola
- NASA is sending astronauts back to the moon. Can you see the Artemis 4 landing sites from Earth?
- The Best Web-based Courses for Ability Advancement
